The news largely focuses on the divestment of ownership in Haleon by pharmaceutical giants GSK and Pfizer. Over the course of many transactions, GSK successfully disposed of its remaining stake in Haleon for approximately $1.5 billion, finalizing its full exit from the consumer health spinoff. In a similar vein, Pfizer carried out its plans to trim down its Haleon stake from 32% to 24%, engaging in massive share sales worth nearly $2.6 billion and $3.5 billion.
These activities stirred up the stock market, leading to Haleon shares rising by 5% due to strong fiscal year results and the implementation of a share buyback scheme. Despite Pfizer's reduction in ownership, Haleon still managed to post its Q1 2024 results, beating EPS expectations. To boot, financial advisors have been increasing Haleon plc's stock popularity, with Morgan Stanley adjusting Haleon shares target, focusing on its Q1 growth forecast.
Institutionally, Haleon remains a favorite, with ownership standing at 50%. The positive news also encompassed Haleon announcing a new CFO – Dawn Allen. The insights provided in the reports largely show Haleon moving forward with strength, despite multiple divestments by former major stakeholders.
Haleon Stocks News Analytics from Wed, 02 Aug 2023 07:00:00 GMT to Sat, 18 May 2024 20:16:00 GMT - Rating 5 - Innovation 3 - Information 8 - Rumor -2
